Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells.

Cancer gene therapy - 1 May 2022

Suzuki Tatsunori, Kishikawa Takahiro, Sato Tatsuyuki, Takeda Norihiko, Sugiura Yuki, Seimiya Takahiro, Sekiba Kazuma, Ohno Motoko, Iwata Takuma, Ishibashi Rei, Otsuka Motoyuki, Koike Kazuhiko

Abstract excerpt

Mutational activation of the KRAS gene occurs in almost all pancreatic ductal adenocarcinoma (PDAC) and is the earliest molecular event in their carcinogenesis. Evidence has accumulated of the metabolic reprogramming in PDAC, such as amino acid homeostasis and autophagic flux. However, the biological effects of KRAS mutation on metabolic reprogramming at the earlier stages of PDAC carcinogenesis are unclear. Here...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic function and diabetes

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 33833413
DOI: 10.1038/s41417-021-00326-4
PMCID: PMC9113932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells.PMID 33833413Read ↗

Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic TumorsSemantic proximity Read ↗

The biological role of metabolic reprogramming in pancreatic cancerSemantic proximity Read ↗

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read ↗

Targeting KRAS: from metabolic regulation to cancer treatmentSemantic proximity Read ↗

KRAS: feeding pancreatic cancer proliferation.Semantic proximity Read ↗

Targeting metabolic reprogramming in KRAS-driven cancers.Semantic proximity Read ↗

Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal MetaplasiaSemantic proximity Read ↗

The complex landscape of pancreatic cancer metabolismSemantic proximity Read ↗

Molecular Pathways Controlling Autophagy in Pancreatic CancerSemantic proximity Read ↗

Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells.Semantic proximity Read ↗

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.